Philip J M Brouwer
Overview
Explore the profile of Philip J M Brouwer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
2194
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Brown S, Antanasijevic A, Sewall L, Garcia D, Brouwer P, Sanders R, et al.
Sci Immunol
. 2025 Jan;
10(103):eadp5218.
PMID: 39823319
Vaccination strategies against HIV-1 aim to elicit broadly neutralizing antibodies (bnAbs) using prime-boost regimens with HIV envelope (Env) immunogens. Epitope mapping has shown that early antibody responses are directed to...
2.
Brinkkemper M, Kerster G, Brouwer P, Tran A, Torres J, Ettema R, et al.
PLoS Pathog
. 2024 Oct;
20(10):e1012558.
PMID: 39361585
An effective human immunodeficiency virus 1 (HIV-1) vaccine will most likely have to elicit broadly neutralizing antibodies (bNAbs) to overcome the sequence diversity of the envelope glycoprotein (Env). So far,...
3.
Brouwer P, Perrett H, Beaumont T, Nijhuis H, Kruijer S, Burger J, et al.
Cell Rep
. 2024 Sep;
43(9):114708.
PMID: 39243373
Lassa fever continues to be a major public health burden in West Africa, yet effective therapies or vaccines are lacking. The isolation of protective neutralizing antibodies against the Lassa virus...
4.
Brown S, Antanasijevic A, Sewall L, Garcia D, Brouwer P, Sanders R, et al.
bioRxiv
. 2024 Apr;
PMID: 38559180
Vaccination strategies against HIV-1 aim to elicit broadly neutralizing antibodies (bnAbs) using prime-boost regimens with HIV envelope (Env) immunogens. Early antibody responses to easily accessible epitopes on these antigens are...
5.
Brouwer P, Perrett H, Beaumont T, Nijhuis H, Kruijer S, Burger J, et al.
bioRxiv
. 2024 Jan;
PMID: 38187682
Lassa fever continues to be a major public health burden in endemic countries in West Africa, yet effective therapies or vaccines are lacking. The isolation of potent and protective neutralizing...
6.
Ronk A, Lloyd N, Zhang M, Atyeo C, Perrett H, Mire C, et al.
Nat Commun
. 2023 Sep;
14(1):5603.
PMID: 37699929
Lassa virus is a member of the Arenaviridae family, which causes human infections ranging from asymptomatic to severe hemorrhagic disease with a high case fatality rate. We have designed and...
7.
Perrett H, Brouwer P, Hurtado J, Newby M, Liu L, Muller-Krauter H, et al.
Cell Rep
. 2023 May;
42(5):112524.
PMID: 37209096
Lassa fever is an acute hemorrhagic fever caused by the zoonotic Lassa virus (LASV). The LASV glycoprotein complex (GPC) mediates viral entry and is the sole target for neutralizing antibodies....
8.
Mariotti S, Chiantore M, Teloni R, Iacobino A, Capocefalo A, Michelini Z, et al.
Biomedicines
. 2023 Feb;
11(2).
PMID: 36831149
The emergence of the new pathogen SARS-CoV-2 determined a rapid need for monoclonal antibodies (mAbs) to detect the virus in biological fluids as a rapid tool to identify infected individuals...
9.
Brinkkemper M, Veth T, Brouwer P, Turner H, Poniman M, Burger J, et al.
iScience
. 2022 Nov;
25(12):105649.
PMID: 36439375
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants poses continuous challenges in combating the virus. Here, we describe vaccination strategies to broaden SARS-CoV-2 and sarbecovirus immunity by...
10.
Sliepen K, Radic L, Capella-Pujol J, Watanabe Y, Zon I, Chumbe A, et al.
Nat Commun
. 2022 Nov;
13(1):7271.
PMID: 36434005
Hepatitis C virus (HCV) infection affects approximately 58 million people and causes ~300,000 deaths yearly. The only target for HCV neutralizing antibodies is the highly sequence diverse E1E2 glycoprotein. Eliciting...